Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pimasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 19/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 2/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 1/20 | 1.00 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimasertib SCHEMBL29604438 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| Pimasertib SCHEMBL29358435 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| Pimasertib SCHEMBL22046269 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| Pimasertib SCHEMBL2720659 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| Pimasertib SCHEMBL18260054 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| Pimasertib SCHEMBL29867955 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| SCHEMBL31108067 | 0.92 | MAP2K1 (0.85) | MAP2K1MAP2K2PRKCZIARS2PDE10A | |
| SCHEMBL2018933 | 0.88 | MAP2K1 (0.79) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL2019046 | 0.88 | MAP2K1 (0.79) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL2018500 | 0.88 | MAP2K1 (0.79) | MAP2K1MAP2K2PRKCZIARS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 532 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50313-E1 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2025-02-25 | — | — | US | claimed |
| US-20240382484-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | THOMAS JEFFERSON UNIVERSITY | 2024-11-21 | — | — | US | claimed |
| WO-2023044386-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2023-03-23 | — | — | WO | claimed |
| EP-3702445-B1 | NOVEL MUSCULOSKELETAL STEM CELL | CELLATOZ THERAPEUTICS INC (KR) | 2022-12-07 | — | — | EP | claimed |
| CN-113631158-A | (S) -N-hydroxy-2- (2- (4-methoxyphenyl) butanamido) thiazole-5-carboxamide and pharmaceutically acceptable salts thereof | 转化药物开发有限责任公司 | 2021-11-09 | — | — | CN | claimed |
| EP-3893863-A1 | <SMALLCAPS/>? ? ?S? ? ? ? ?()-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2021-10-20 | — | — | EP | claimed |
| EP-3702445-A2 | NOVEL MUSCULOSKELETAL STEM CELL | Cellatoz Therapeutics, Inc. (KR) | 2020-09-02 | — | — | EP | claimed |
| WO-2020123414-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-06-18 | — | — | WO | claimed |
| EP-3643777-A1 | NOVEL MUSCULOSKELETAL STEM CELL AND MEDIUM FOR INDUCING DIFFERENTIATION OF MUSCULOSKELETAL STEM CELL | Cellatoz Therapeutics, Inc. (KR) | 2020-04-29 | — | — | EP | claimed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| EP-1802579-B1 | Derivatives of 3-arylaminopyridine | MERCK SERONO SA (CH) | 2013-11-20 | — | — | EP | claimed |
| WO-2013152165-A1 | METHODS FOR TREATING CANCER USING PI3K INHIBITOR AND MEK INHIBITOR | SANOFI (FR) | 2013-10-10 | — | — | WO | claimed |
| WO-2013059320-A1 | TREATMENT OF CANCERS WITH MUTANT NPM1 WITH MEK INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-04-25 | — | — | WO | claimed |
| US-20120295889-A1 | 3-Arylamino Pyridine Derivatives | MERCK SERONO S.A. (CH) | 2012-11-22 | — | — | US | claimed |
| US-8198457-B2 | 3-arylamino pyridine derivatives | MERCK SERONO S.A. (CH) | 2012-06-12 | — | — | US | claimed |
| US-20110224192-A1 | 3-Arylamino Pyridine Derivatives | MERCK SERONO SA (CH) | 2011-09-15 | — | — | US | claimed |
| US-7956191-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2011-06-07 | — | — | US | claimed |
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2009-04-09 | — | — | US | claimed |
| EP-1802579-A1 | 3-ARYLAMINO PYRIDINE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2007-07-04 | — | — | EP | claimed |
| WO-2006045514-A1 | 3-ARYLAMINO PYRIDINE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-05-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224192-A1 | 3-Arylamino Pyridine Derivatives | MAPK3, BRAF, NRAS | MAP2K1 105/4885MAP2K2 104/4885PRKCZ 1803/4885 |
| US-20120295889-A1 | 3-Arylamino Pyridine Derivatives | MAPK3, BRAF, NRAS | MAP2K1 105/4885MAP2K2 104/4885PRKCZ 1803/4885 |
| US-20240382484-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | PDPK1, PLK3, PLK2 | MAP2K1 207/4885MAP2K2 205/4885PRKCZ 598/4885 |
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | CDK4, BRAF, CDK3 | MAP2K1 119/4885MAP2K2 116/4885PRKCZ 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.